Leadership Team

Dr. Horner has a strong background in neuropharmacology and medicinal chemistry, and is an internationally recognized scientist and pharmaceutical executive. He is skilled at translating basic science into clinical drugs and has driven multiple innovative therapies to market.

Shirley Milner has dual expertise in real estate and biotechnology investments, specializing in cross-sector capital deployment and channeling resources into high-growth industries.

Sophia Costa is a seasoned cross-industry investor and strategist with experience spanning technology, AI, biotech, healthcare, and sustainability. She serves as an independent director and strategic advisor across international ventures.

Laura Devasini is an investment-focused consultant specializing in the intersection of biotech and AI. She has extensive practical experience in AI cancer projects, bridging research and commercialization.

Dennis Liotta is one of the world's leading medicinal chemists. As Executive Director of the Emory Institute for Drug Development, Dr. Liotta oversees innovative programs that bridge academic research with pharmaceutical application, accelerating the path from laboratory discoveries to real-world medicines.

Homer Pearce is a distinguished scientist with decades of leadership in pharmaceutical R&D, specializing in oncology and innovative drug design. As former Vice President of Cancer Research at Eli Lilly, he directed pioneering programs that advanced novel therapies from concept to clinical application.

Jeremy Graff brings extensive expertise in oncology research and therapeutic target selection. With years of experience at Eli Lilly as a Research Fellow, he contributed to advancing novel approaches in cancer biology, driving programs that bridge early discovery with clinical translation.

Russ Greiner is an internationally recognized leader in artificial intelligence and machine learning, with a particular focus on applications in health and precision medicine. As a Professor at the University of Alberta and a Fellow-in-Residence at the Alberta Machine Intelligence Institute, he has been at the forefront of developing advanced algorithms that transform medical data into actionable insights.

Jonathan Glass is a leading neurologist and pathologist whose career has been dedicated to advancing the understanding and treatment of amyotrophic lateral sclerosis (ALS). As Professor at Emory University and Director of the Emory ALS Center, he has built one of the foremost programs for ALS research and patient care in the world.

Thomas Wichmann is a renowned neurologist specializing in movement disorders, with decades of research and clinical experience in Parkinson’s disease and related neurological conditions. As Professor of Neurology at Emory University and Associate Director of the Movement Disorder Division, he has played a key role in advancing translational research that bridges neuroscience discoveries with patient-centered care.